# Medizen Humancare lnc.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medizen-humancare-lnc

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.medizencare.com
- Total disclosed funding: $1.4M
- Latest round: Series A (Mar 13, 2014)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2012, Medizen Humancare lnc. operates as a research company that provides genomic analysis for predicting vulnerability of individual patient diseases. In 2013, Medizen Humancare lnc. was registered as a genetic testing center and genetic research center. In 2014, Medizen Humancare lnc. became a full member of the Korea Genome Industry Council at Korea Biotechnology Industry Organization. In 2016, the company was listed on KONEX. In 2018, the company was certified  a Highest Grade (Grade P) Institution for Accurate Evaluation in Genetic Testing in 2017, for the third consecutive year. In May 2020, Daedeok Venture Partners and Korea Investment Partners acquired 90,624 shares in Medizen Humancare lnc. at KRW 16,000 apiece for KRW 1.45 billion, in a PIPE deal. The CEO of the company is Dong Jik Shin.


Medizen Humancare lnc. provides healthcare genetic disease prediction and customized healthcare services. Some of its main products include M-CHECK, an analysis kits for identifying genetic disease using genomic variation package, and MELTHY (DTC), DNA analysis service. 

Medizen Humancare lnc. generate revenues through B2B transactions. The company provides genetic analysis services to hospitals and medical institutions in South Korea and China.

## Funding rounds

- Series A, Mar 13, 2014, $1.4M — Medici Investment, Myventure Partners

## Investors

- Medici Investment (https://capitalatlas.ai/funds/medici-investment) — Series A
- Myventure Partners (https://capitalatlas.ai/funds/myventure-partners) — Series A